CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects w...
Phase 2
Indianapolis, Indiana, United States and 24 other locations
American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The s...
Phase 4
Indianapolis, Indiana, United States and 30 other locations
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...
Phase 3
Avon, Indiana, United States and 125 other locations
The primary purpose of this phase 3b study is to assess efficacy after transition from a current DMT to ublituximab, as measured by T1 Gadolinium (Gd...
Phase 3
Indianapolis, Indiana, United States and 20 other locations
A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple...
Phase 3
Indianapolis, Indiana, United States and 192 other locations
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...
Phase 3
Avon, Indiana, United States and 117 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS)....
Phase 3
Indianapolis, Indiana, United States and 301 other locations
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...
Phase 3
Indianapolis, Indiana, United States and 239 other locations
Clinical trials
Research sites
Resources
Legal